Drugs in Dev. Neurology
Phase II
Denmark 
Lundbeck Expands Lu AG09222 Migraine Trial to Include IV Dose Arm
Details : Lundbeck is developing Lu AG09222, an investigational monoclonal antibody (mAb) with an innovative mode of action, designed to bind and inhibit pituitary adenylate cyclase-activating polypeptide.
Product Name : Lu AG09222
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2025
Lundbeck Launches a Phase II Study for Potential New Treatment of Multiple System Atrophy
Details : Lu AF82422 is a human monoclonal antibody (mAb) targeting the toxic alpha-synuclein protein known to be a pathological hallmark of MSA. The compound is thought to work like the body’s natural immune system to clear these harmful proteins.
Product Name : Lu AF82422
Product Type : Antibody
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Foliglurax
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson’s disease
Details : The phase IIa study of Lundbeck's selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson's disease did not meet the primary study endpoint.
Product Name : PXT 002331
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2020
Lead Product(s) : Foliglurax
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lundbeck announces phase IIa study results of Lu AG06466 in adults with Tourette Syndrome
Details : Insufficient efficacy to proceed with development of Lu AG06466 in Tourette Syndrome, However, safety and tolerability of the agent allows for further studies in additional indications will proceed.
Product Name : Lu AG06466
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2020
Reset All
